Company Focus
Galderma
Latest Galderma News
Biotechnology
The US Food and Drug Administration (FDA) has approved Galderma’s Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. 14 August 2024
Dermatology News
Insights
Company Spotlight
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.
Latest News & Features of interest to Galderma
Biotechnology
Swiss independent dermatology specialist Galderma has released positive data from three pivotal Phase III trials in atopic dermatitis and prurigo nodularis – ARCADIA 1 and 2 and OLYMPIA 1, respectively. 13 October 2023
Biotechnology
At the European Academy of Dermatology and Venerology (EADV) congress in Berlin, AbbVie is presenting positive results from the Phase IIb NCT04927975 study. 12 October 2023
Biosimilars
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Icelandic firm Alvotech’s Biologics License Application (BLA) for AVT04, a biosimilar candidate to Johnson & Johnson Stelara (ustekinumab). 12 October 2023
Biotechnology
Swedish biotech Promore Pharma will soon run out of money, and has begun liquidation proceedings, the company announced. 12 October 2023
Biotechnology
San Diego, USA-based biotech AnaptysBio saw its shares edge up 3.6% to $19.95, after it released results from the Phase III GEMINI-1 trial evaluating the safety and efficacy of imsidolimab (interleukin (IL)-36R MAb) in patients with generalized pustular psoriasis (GPP) flares. 10 October 2023
Pharmaceutical
Privately-held Danish dermatology specialist LEO Pharma has named Professor Alexander Egeberg, a globally recognized dermatologist and top key opinion leader as the company’s new vice president, head of global medical affairs. 9 October 2023
Pharmaceutical
Leading Indian drugmaker Sun Pharmaceutical Industries today revealed that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for deuruxolitinib, an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2, for the treatment of adults with moderate to severe alopecia areata. 6 October 2023
Biotechnology
US immuno-dermatology specialist biotech Dermavant Sciences, a subsidiary of Roivant Sciences, has appointed John Darden as vice president of marketing. 6 October 2023
Biotechnology
Privately-held Swiss dermatology company Galderma has announced some bad news relating to its pending Biologics License Application (BLA) for relabotulinumtoxinA (QM-1114) to the US Food and Drug Administration (FDA). 3 October 2023
Biotechnology
The US Food and Drug Administration (FDA) has issued a complete response letter for the lebrikizumab biologic license application (BLA) for the treatment of moderate-to-severe atopic dermatitis (eczema), the drug’s developer, US pharma major Eli Lilly, announced yesterday. 3 October 2023
Latest In Brief for Galderma
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Latest Dermatology Ones To Watch News
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
18 September 2024
13 August 2024
24 July 2024
17 May 2024
Dermatology Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze